Time to Reconsider Dabigatran 110 mg in the USA

American Journal of Cardiovascular Drugs

Volumn 15, Issue 5, 2015, Pages 307-309

  Hernandez, Inmaculada ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT;

AFRICAN AMERICAN; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; UNITED STATES; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); COMPLICATION; DOSE RESPONSE; DRUG APPROVAL; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; HUMANS; STROKE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84942988496     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-015-0137-0     Document Type: Article

References (11)

1. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365(11):1052–4.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
3. European Medicines Agency. European Public Assessment Report for Pradaxa. [cited 2015 May 28]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf.
4. Therapeutic Goods Administration. Product Information for Pradaxa. [cited 2015 May 28]; Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-01177-3.
5. Prazaxa (dabigatran etexilate) Approved in Japan for Stroke Prevention in Atrial Fibrillation 2011 [cited 2015 May 28]; Available from: http://www.businesswire.com/news/home/20110121005341/en/PRAZAXA%C2%AE-dabigatran-etexilate-Approved-Japan-Stroke-Prevention#.VWfTfEbbh-A.
6. Center for Drug Evaluation and Research. Approval Package for Pradaxa. 2010 [cited 2015 May 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000Approv.pdf.
7. Beasley BN, Unger EF, Temple R. Anticoagulant options—why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788–90.
8. Kowey PR, Naccarelli GV. The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out. Am J Med. 2012;125(8):732.
9. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation. 2015;131(2):157–64.
10. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24.
11. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014;111(5):933–42.